Promising mRNA Vaccine Shows Potential Against Severe Skin Cancer

A novel treatment approach using mRNA technology is generating significant hope for individuals battling severe forms of skin cancer. Preliminary results from an ongoing study indicate that individually tailored mRNA vaccines, when administered alongside another medication, have successfully slowed tumor progression and decreased the spread of cancer.

Lars Ny, a professor and chief physician at Sahlgrenska University Hospital, described the findings as "big news," expressing a sentiment of cautious optimism after previous disappointments with similar treatments. "We have been let down so many times with similar treatments," Ny stated, but added, "This is precision medicine at its best."

“

This is big news. We have been let down so many times with similar treatments. This is precision medicine at its best.

The treatment involves creating a personalized vaccine based on the specific mutations found in a patient's tumor. This vaccine then trains the patient's immune system to target and eliminate cancer cells. The process, which takes about a month to produce the vaccine in the U.S. and ship it to the patient, is considered remarkable given the complexity involved.

Results from a larger study involving approximately 1,100 patients have not yet been published in a scientific journal. However, the companies behind the treatment, Merck and Moderna, have announced positive outcomes. The vaccine is used as an additional therapy for diagnosed cancer, not as a preventative measure. Researchers are also exploring its potential efficacy in treating other cancers, such as pancreatic and bladder cancer, with early studies underway.

“

The process of developing the vaccine takes a month, that it can be done within that timeframe is fantastic.